Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02053610
Registration number
NCT02053610
Ethics application status
Date submitted
25/11/2013
Date registered
3/02/2014
Date last updated
14/09/2018
Titles & IDs
Public title
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Query!
Scientific title
An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.
Query!
Secondary ID [1]
0
0
2009-012476-28; CLL1
Query!
Secondary ID [2]
0
0
BO21004 (Stage 2)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphocytic Leukemia, Chronic
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - obinutuzumab
Treatment: Drugs - rituximab
Treatment: Drugs - chlorambucil
Experimental: obinutuzumab + chlorambucil (GClb) - Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
Active comparator: rituximab + chlorambucil (RClb) - Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
Active comparator: Chlorambucil (Clb) - Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
Treatment: Drugs: obinutuzumab
1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
Treatment: Drugs: rituximab
375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Treatment: Drugs: chlorambucil
Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Query!
Timepoint [1]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Progression Free Survival Events
Query!
Assessment method [2]
0
0
Percentage of Participants with Progression Free Survival Events: progression, relapse, or death.
Query!
Timepoint [2]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [1]
0
0
Progression Free Survival Based on Independent Review Committee (IRC) Data
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Query!
Timepoint [1]
0
0
Randomization to clinical cutoff of 09 May 2013 (median observation 18.7 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data
Query!
Assessment method [2]
0
0
Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.
Query!
Timepoint [2]
0
0
Randomization to clinical cutoff of 09 May 2013 (median observation 18.7 months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With End of Treatment Response (EOTR)
Query!
Assessment method [3]
0
0
EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. Complete Response (CR) required: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. Partial Response (PR) required the following for at least 2 months from end of treatment: =50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a = 50% reduction in lymphadenopathy OR =50% reduction of liver enlargement OR =50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or =50% increase, Platelets \>100 x 10\^9/L or =50% increase, Hemoglobin 11 g/dL or =50% increase.
Query!
Timepoint [3]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Best Overall Response
Query!
Assessment method [4]
0
0
Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi, PR or nodular Partial Response (nPR). CR required all of the following: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: =50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a = 50% reduction in lymphadenopathy OR =50% reduction of liver enlargement OR =50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or =50% increase, Platelets \>100 x 10\^9/L or =50% increase, Hemoglobin 11 g/dL or =50% increase.
Query!
Timepoint [4]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [5]
0
0
Event Free Survival
Query!
Assessment method [5]
0
0
Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Query!
Timepoint [5]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [6]
0
0
Overall Survival
Query!
Assessment method [6]
0
0
Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.
Query!
Timepoint [6]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [7]
0
0
Duration of Response
Query!
Assessment method [7]
0
0
Duration of Response was defined as the date the response \[either Complete Response (CR) or Partial Response (PR)\] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines.
Query!
Timepoint [7]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Molecular Remission at the End of Treatment
Query!
Assessment method [8]
0
0
Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).
Query!
Timepoint [8]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [9]
0
0
Time to Re-Treatment/New Anti-leukemic Therapy
Query!
Assessment method [9]
0
0
Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy.
Query!
Timepoint [9]
0
0
Randomization to clinical cutoff (median observation 59.4 months)
Query!
Secondary outcome [10]
0
0
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire
Query!
Assessment method [10]
0
0
The EORTC Quality of Life Questionnaire (QLQ-C30) was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
Query!
Timepoint [10]
0
0
Baseline and Cycle 4 Day 1 (Cy4D1)
Query!
Secondary outcome [11]
0
0
European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire
Query!
Assessment method [11]
0
0
EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
Query!
Timepoint [11]
0
0
Baseline and Cycle 4 Day 1 (Cy4D1)
Query!
Eligibility
Key inclusion criteria
* Adults >/=18 years
* Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
* Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
* Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70 ml/min.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Prior CLL therapy
* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
* History of other malignancy unless the malignancy has been in remission without treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone
* Positive hepatitis serology (HBV, HCV) or positive HIV or Human T-Cell Leukemia Virus (HTLV) testing
* Patients with active infection requiring systemic treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/12/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
787
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Gosford
Query!
Recruitment hospital [3]
0
0
- Kogarah
Query!
Recruitment hospital [4]
0
0
- Liverpool
Query!
Recruitment hospital [5]
0
0
- St. Leonards
Query!
Recruitment hospital [6]
0
0
- Sydney
Query!
Recruitment hospital [7]
0
0
- Greenslopes
Query!
Recruitment hospital [8]
0
0
- Southport
Query!
Recruitment hospital [9]
0
0
- Woolloongabba
Query!
Recruitment hospital [10]
0
0
- Kurralta Park
Query!
Recruitment hospital [11]
0
0
- Frankston
Query!
Recruitment hospital [12]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [4]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [5]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [6]
0
0
2139 - Sydney
Query!
Recruitment postcode(s) [7]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [8]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [9]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [10]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [11]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [12]
0
0
3168 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Wisconsin
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Buenos Aires
Query!
Country [6]
0
0
Argentina
Query!
State/province [6]
0
0
Rosario
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Graz
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
Innsbruck
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Wien
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
GO
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
MG
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
RS
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
SP
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Pleven
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Plovdiv
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Sofia
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Varna
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Vratsa
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Alberta
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Manitoba
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Nova Scotia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Ontario
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
Croatia
Query!
State/province [24]
0
0
Zagreb
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Brno
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Hradec Kralove
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Praha 2
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Aalborg
Query!
Country [29]
0
0
Denmark
Query!
State/province [29]
0
0
København
Query!
Country [30]
0
0
Denmark
Query!
State/province [30]
0
0
Odense
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Vejle
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Århus
Query!
Country [33]
0
0
Egypt
Query!
State/province [33]
0
0
Cairo
Query!
Country [34]
0
0
Estonia
Query!
State/province [34]
0
0
Tallinn
Query!
Country [35]
0
0
Estonia
Query!
State/province [35]
0
0
Tartu
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Angers
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Bobigny
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Caen
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Clermont Ferrand
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Creteil
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Le Mans
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Lille
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Lyon
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Marseille
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Montpellier
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Nantes
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Paris
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Pessac
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Pierre Benite
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Poitiers
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Reims
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Rennes
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Rouen
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Toulouse
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Tours
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Vandoeuvre Les Nancy
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Ahaus
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Amberg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Ansbach
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Bamberg
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Berlin
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Bonn
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Bremen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Delitzsch
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Detmold
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Dresden
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Duisburg
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Erlangen
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Eschweiler
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Essen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Esslingen
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Frankfurt am Main
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Frankfurt an der Oder
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Frankfurt
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Frechen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Freiburg
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Giessen
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Greifswald
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Göttingen
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Hamburg
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Hamm
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Hannover
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Heidelberg
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Homburg/Saar
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Kaiserslautern
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Karlsruhe
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Kempten
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Kiel
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Koblenz
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Koeln
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Kronach
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Köln
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Landshut
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Lebach
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Leer
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Lemgo
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Lörrach
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Lüdenscheid
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Magedburg
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Mainz
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Mannheim
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
Muenchen
Query!
Country [103]
0
0
Germany
Query!
State/province [103]
0
0
Mutlangen
Query!
Country [104]
0
0
Germany
Query!
State/province [104]
0
0
München
Query!
Country [105]
0
0
Germany
Query!
State/province [105]
0
0
Neunkirchen/Saar
Query!
Country [106]
0
0
Germany
Query!
State/province [106]
0
0
Nürnberg
Query!
Country [107]
0
0
Germany
Query!
State/province [107]
0
0
Oldenburg
Query!
Country [108]
0
0
Germany
Query!
State/province [108]
0
0
Porta Westfalica
Query!
Country [109]
0
0
Germany
Query!
State/province [109]
0
0
Ravensburg
Query!
Country [110]
0
0
Germany
Query!
State/province [110]
0
0
Recklinghausen
Query!
Country [111]
0
0
Germany
Query!
State/province [111]
0
0
Regensburg
Query!
Country [112]
0
0
Germany
Query!
State/province [112]
0
0
Rostock
Query!
Country [113]
0
0
Germany
Query!
State/province [113]
0
0
Rüsselsheim
Query!
Country [114]
0
0
Germany
Query!
State/province [114]
0
0
Saarbruecken
Query!
Country [115]
0
0
Germany
Query!
State/province [115]
0
0
Sindelfingen
Query!
Country [116]
0
0
Germany
Query!
State/province [116]
0
0
Stuttgart
Query!
Country [117]
0
0
Germany
Query!
State/province [117]
0
0
Trier
Query!
Country [118]
0
0
Germany
Query!
State/province [118]
0
0
Tübingen
Query!
Country [119]
0
0
Germany
Query!
State/province [119]
0
0
Ulm
Query!
Country [120]
0
0
Germany
Query!
State/province [120]
0
0
Villingen-Schwenningen
Query!
Country [121]
0
0
Germany
Query!
State/province [121]
0
0
Weilheim
Query!
Country [122]
0
0
Germany
Query!
State/province [122]
0
0
Wendlingen
Query!
Country [123]
0
0
Germany
Query!
State/province [123]
0
0
Witten
Query!
Country [124]
0
0
Germany
Query!
State/province [124]
0
0
Worms
Query!
Country [125]
0
0
Germany
Query!
State/province [125]
0
0
Wuerzburg
Query!
Country [126]
0
0
Germany
Query!
State/province [126]
0
0
Würzburg
Query!
Country [127]
0
0
Hong Kong
Query!
State/province [127]
0
0
Hong Kong
Query!
Country [128]
0
0
Italy
Query!
State/province [128]
0
0
Calabria
Query!
Country [129]
0
0
Italy
Query!
State/province [129]
0
0
Emilia-Romagna
Query!
Country [130]
0
0
Italy
Query!
State/province [130]
0
0
Lazio
Query!
Country [131]
0
0
Italy
Query!
State/province [131]
0
0
Liguria
Query!
Country [132]
0
0
Italy
Query!
State/province [132]
0
0
Lombardia
Query!
Country [133]
0
0
Italy
Query!
State/province [133]
0
0
Piemonte
Query!
Country [134]
0
0
Italy
Query!
State/province [134]
0
0
Sardegna
Query!
Country [135]
0
0
Italy
Query!
State/province [135]
0
0
Sicilia
Query!
Country [136]
0
0
Italy
Query!
State/province [136]
0
0
Umbria
Query!
Country [137]
0
0
Mexico
Query!
State/province [137]
0
0
Aguascalientes
Query!
Country [138]
0
0
Mexico
Query!
State/province [138]
0
0
Culiacan
Query!
Country [139]
0
0
Mexico
Query!
State/province [139]
0
0
Hermosillo
Query!
Country [140]
0
0
Mexico
Query!
State/province [140]
0
0
Monterrey
Query!
Country [141]
0
0
Mexico
Query!
State/province [141]
0
0
San Luis Potosi
Query!
Country [142]
0
0
Netherlands
Query!
State/province [142]
0
0
Delftzijl
Query!
Country [143]
0
0
Netherlands
Query!
State/province [143]
0
0
Enschede
Query!
Country [144]
0
0
Netherlands
Query!
State/province [144]
0
0
Leeuwarden
Query!
Country [145]
0
0
Netherlands
Query!
State/province [145]
0
0
Nieuwegein
Query!
Country [146]
0
0
New Zealand
Query!
State/province [146]
0
0
Auckland
Query!
Country [147]
0
0
New Zealand
Query!
State/province [147]
0
0
Christchurch
Query!
Country [148]
0
0
Romania
Query!
State/province [148]
0
0
Bucharest
Query!
Country [149]
0
0
Romania
Query!
State/province [149]
0
0
Bucuresti
Query!
Country [150]
0
0
Romania
Query!
State/province [150]
0
0
Targu-mures
Query!
Country [151]
0
0
Russian Federation
Query!
State/province [151]
0
0
Kazan
Query!
Country [152]
0
0
Russian Federation
Query!
State/province [152]
0
0
Nizhny Novgorod
Query!
Country [153]
0
0
Russian Federation
Query!
State/province [153]
0
0
Penza
Query!
Country [154]
0
0
Russian Federation
Query!
State/province [154]
0
0
Perm
Query!
Country [155]
0
0
Russian Federation
Query!
State/province [155]
0
0
Rostov-na-donu
Query!
Country [156]
0
0
Russian Federation
Query!
State/province [156]
0
0
UFA
Query!
Country [157]
0
0
Slovakia
Query!
State/province [157]
0
0
Bratislava
Query!
Country [158]
0
0
Spain
Query!
State/province [158]
0
0
Asturias
Query!
Country [159]
0
0
Spain
Query!
State/province [159]
0
0
Barcelona
Query!
Country [160]
0
0
Spain
Query!
State/province [160]
0
0
Cadiz
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Cantabria
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Guipuzcoa
Query!
Country [163]
0
0
Spain
Query!
State/province [163]
0
0
LA Coruña
Query!
Country [164]
0
0
Spain
Query!
State/province [164]
0
0
Navarra
Query!
Country [165]
0
0
Spain
Query!
State/province [165]
0
0
Tenerife
Query!
Country [166]
0
0
Spain
Query!
State/province [166]
0
0
Valencia
Query!
Country [167]
0
0
Spain
Query!
State/province [167]
0
0
Jaen
Query!
Country [168]
0
0
Spain
Query!
State/province [168]
0
0
Las Palmas
Query!
Country [169]
0
0
Spain
Query!
State/province [169]
0
0
Madrid
Query!
Country [170]
0
0
Spain
Query!
State/province [170]
0
0
Malaga
Query!
Country [171]
0
0
Spain
Query!
State/province [171]
0
0
Murcia
Query!
Country [172]
0
0
Spain
Query!
State/province [172]
0
0
Salamanca
Query!
Country [173]
0
0
Spain
Query!
State/province [173]
0
0
Sevilla
Query!
Country [174]
0
0
Spain
Query!
State/province [174]
0
0
Toledo
Query!
Country [175]
0
0
Spain
Query!
State/province [175]
0
0
Zaragoza
Query!
Country [176]
0
0
Switzerland
Query!
State/province [176]
0
0
Aarau
Query!
Country [177]
0
0
Switzerland
Query!
State/province [177]
0
0
Basel
Query!
Country [178]
0
0
Switzerland
Query!
State/province [178]
0
0
Bern
Query!
Country [179]
0
0
Switzerland
Query!
State/province [179]
0
0
Chur
Query!
Country [180]
0
0
Switzerland
Query!
State/province [180]
0
0
Luzern
Query!
Country [181]
0
0
Switzerland
Query!
State/province [181]
0
0
St. Gallen
Query!
Country [182]
0
0
Switzerland
Query!
State/province [182]
0
0
Zürich
Query!
Country [183]
0
0
Thailand
Query!
State/province [183]
0
0
Bangkok
Query!
Country [184]
0
0
Thailand
Query!
State/province [184]
0
0
Khon Kaen
Query!
Country [185]
0
0
United Kingdom
Query!
State/province [185]
0
0
Bournemouth
Query!
Country [186]
0
0
United Kingdom
Query!
State/province [186]
0
0
Cambridge
Query!
Country [187]
0
0
United Kingdom
Query!
State/province [187]
0
0
Canterbury
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
Cardiff
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Cottingham
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
Edinburgh
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Glasgow
Query!
Country [192]
0
0
United Kingdom
Query!
State/province [192]
0
0
Leicester
Query!
Country [193]
0
0
United Kingdom
Query!
State/province [193]
0
0
London
Query!
Country [194]
0
0
United Kingdom
Query!
State/province [194]
0
0
Nottingham
Query!
Country [195]
0
0
United Kingdom
Query!
State/province [195]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
German CLL Study Group
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/industry
Query!
Name [2]
0
0
Genentech, Inc.
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is \>6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02053610
Query!
Trial related presentations / publications
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Bottcher S, Langerak AW, Kneba M, Hallek M. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02053610
Download to PDF